期刊文献+

B型肉毒毒素保护性抗原Hc在大肠杆菌中的可溶性高表达 被引量:8

High-Level and Soluble Expressions of Botulinum Neurotoxin Serotype B Protective Antigen Hc Domain in Escherichia coli
下载PDF
导出
摘要 目的:通过序列优化及表达条件改进,在大肠杆菌中高效可溶性表达B型肉毒毒素保护性抗原Hc(Bont/B-Hc)。方法:对Bont/B-Hc基因片段优化,用大肠杆菌常用密码子替换稀有密码子,并将(G+C)含量由76.2%降至56.3%;人工合成多条具有重叠互补序列的寡核苷酸片段,采用重叠延伸PCR方法获得了Bont/B-Hc的全长基因,并构建了原核可溶性表达载体;将经酶切和测序鉴定正确的重组质粒转化大肠杆菌BL21(DE3)感受态细胞,用IPTG诱导Bont/B-Hc的表达并进行纯化及Western印迹鉴定。结果和结论:目的蛋白在大肠杆菌BL21(DE3)中获得了可溶性高表达,占菌体裂解液上清总蛋白的26.7%,表达量达到30mg/L,是目前国内外已知表达的最高水平;经Ni柱一步纯化后,目的蛋白纯度可达到80.3%,为肉毒毒素中和抗体的制备及亚单位疫苗的研究奠定了基础。 Objective: To explore the high-level and soluble expression of the reconstructed protective antigen He fragment of botulinum neurotoxin serotype B (Bont/B-Hc) in E.coli by optimizing the sequence and expression conditions. Methods: The gene encoding Bont/B-Hc was cloned and optimized by replacing rare codons with frequent ones in E.coli and the content of GC pairs decreased from 76.2% to 56.3%. The reconstructed gene was synthesized by overlapping PCR and cloned into prokaryotic soluble expression vector. The recombinant plasmid was then introduced into E.coli BL21(DE3). Bont/B-Hc was expressed, purified and identified by Western-blot. Results and conclusions: Reconstructed He gene was expressed in E.coli BL21(DE3) in soluble form which covered 26.7% total proteins in the supematant of sonicated bacteria. It can be high as 30 mg/L and there was no reports about higher expression before. When purified with Ni column, He covered 80.3% total proteins. This will be an important basis for the produce of neutralizing antibodies and sub-unit vaccines of butulinum neurotoxin serotype B.
出处 《生物技术通讯》 CAS 2008年第3期365-367,共3页 Letters in Biotechnology
关键词 B型肉毒毒素 保护性抗原Hc 可溶性高表达 botulinum nurotoxin serotype B protective antigen He high-level and soluble expression
  • 相关文献

参考文献10

  • 1Gill D M. Bacterial toxins: a table of lethal amounts[J]. Microbiol Rev, 1982,46(1):86-94.
  • 2Amon S S, Schechter R, Inglesby T V, et al. Botulinum toxin as a biological weapon: medical and public health management [J]. JAMA, 2001,285(8):1059-1070.
  • 3Scott A B, Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey[J]. Mov Disord, 1988,3(4):333- 335.
  • 4Schantz E J, Johnson E A. Properties and use of botulinum toxin and other microbial neurotoxins in medicine [J]. Microbiol Rev, 1992,56(1):80-99.
  • 5Niemann H. Clostridium neurotoxins-proposal of a common nomenclature[J]. Toxicon, 1992,30:223-225.
  • 6LaPenotiere H F, Clayton M A, Middlebrook J L. Expression of a large nontoxic fragment of botulinum neurotoxin serotype A and its use as a immunogen[J]. Toxicon, 1995,33:1383-1386.
  • 7Clayton M A, Clayton J M, Brown D R, et al. Protective vaccination with a recombinant ragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli [J]. Infect Immun, 1995,63:2738-2742.
  • 8Clare J J, Rayment F B, Ballantine S P, et al. High-level expression of tetanus toxin fragment C in pichia pastoris strains containing multiple tandem integrations of gene[J]. Bio/Technology, 1991, 9:455-460.
  • 9Tavallaie M, Chenal A, Gillet D, et al. Interaction between the two subdomains of the C-terminal part of the betulinum neurotoxin A is essential for the generation of protective antibodies [J]. FEBS, 2004,572:299-306.
  • 10Baldwin M R, Tepp W H, Pier C L, et al. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E[J]. Infeet Immun, 2005,73(10):6998- 7005.

同被引文献66

引证文献8

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部